$100 Million: Healthcare Giants Form Partnership For Eye Disease Treatment

A Game-Changer in Biotech: Aldeyra Therapeutics and AbbVie's Exclusive Agreement.

In a groundbreaking development in the biotech industry, Aldeyra Therapeutics, a leading clinical-stage biotechnology company, has entered into an exclusive option agreement with pharmaceutical giant AbbVie. This agreement pertains to the license to develop and commercialize Reproxalap, a novel treatment developed by Aldeyra for dry eye disease.

Under th…